Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0002048500-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-05 | 2026-01-02 | BBNX | Mensinger Mike | Chief Product Off | S - Sale | $29.61 | -7,800 | 83.0K | -9% | -$231.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | S | D | 7,200 | $29.56 | 83,552 | D | — | — | (F2) The weighted average sale price for the transaction reported was $29.56 and the range of prices were between $29.05 and $30.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2026-01-02 | S | D | 600 | $30.20 | 82,952 | D | — | — | (F3) The weighted average sale price for the transaction reported was $30.1969 and the range of prices were between $30.10 and $30.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |